MorphoSys AG (NASDAQ:MOR) Q3 2019 Earnings Conference Call - Final Transcript
Oct 30, 2019 • 09:00 am ET
Ladies and gentlemen, welcome to the MorphoSys Q3 Result 2019 Conference Call.[Operator Instructions] After the presentation there will be an opportunity to ask questions. Please note that we can only take your questions if you are registered by name. [Operator Instructions]
Now I would like to turn the conference call over to Sarah Fakih. Please go ahead.
Good afternoon. Good morning and welcome to our Q3 2019 conference call and webcast. My name is. Sarah Fakih and I'm the Head of Corporate Communications and Investor Relations at MorphoSys. Before we start, I would like to remind you that during this conference call, we will present and discuss certain forward-looking statements concerning the development of MorphoSys' core technologies the progress of its current research and development programs and the initiation of additional programs.
Should actual results differ from the Company's assumptions and ensuing actions may differ from those anticipated. You are therefore cautioned not to place undue reliance on such forward-looking statements, which speak only of the date hereof. With me on the call today are Jean-Paul Kress, our Chief Executive Officer, Jens Holstein, our Chief Financial Officer and Malte Peters, our Chief Development Officer.In the presentation. Jean-Paul will start by giving you an operational review of the third quarter as well as an outlook for the rest of this year after that. Jens will review the financial results of the third quarter and the first 9 months of 2019. After the presentation, we will all be available for your questions. You will find the slide deck for this presentation on our corporate website with this, I would now like to hand over to Jean-Paul Kress.
Thank you, Sarah. And also from me a warm welcome to our Q3 2019 earnings call. Yesterday was a very important day for the company, on which we made great progress on our main priorities. We published impressive results on our real world data approach, confirming our regulatory strategy around our L-MIND trial. With this data, we were able to deliver a critical component of the BLA filing package to the FDA.
The rolling submission to the FDA was initiated and we already submitted the first preclinical data package. Another top priority for us is the tafasitamab partnership, I have made clear that I am open to broad partnership settings including a US co-promotion. Our partnering approach follows the goal to maximize the value of tafasitamab and the pipeline in the product value proposition.
We are also finalizing buildup of our US commercial organization and we are executing on a flawless US pre-launch plan. In our proprietary clinical pipeline, we are accelerating the development of our anti-CD38 antibody, MOR202, for which the start of the clinical trial in membranous nephropathy is imminent.
Lastly, we were encouraged by the latest news from Biogen on aducanumab and what this may represent for patients, their families and for the scientific community, though it is premature to draw any conclusions about the investigations of Gantenerumab by our partner Roche as